Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy-Reference-Cited by-同舟云学术

Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy

Published:2021-11-16 Issue:sup1 Volume:24 Page:71-83
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Abraham Ivo¹²³⁴^ORCID,Onyekwere Uchenna⁵,Deniz Baris⁵,Moran Donald⁶^ORCID,Chioda Marc⁶,MacDonald Karen⁴^ORCID,Huang Huan⁶

Affiliation:

1. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA

2. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA

3. University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA

4. Matrix45, Tucson, AZ, USA

5. ZS Associates, Evanston, IL, USA

6. G1 Therapeutics, Inc., Research Triangle Park, NC, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.2014163

Reference52 articles.

1. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors

2. Chemotherapy and signaling

3. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

4. Economic Burden of Haematological Adverse Effects in Cancer Patients

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Solid Lipid Nanoparticles for Delivery of 5-Fluorouracil and Andrographolide: A Combination Approach for the Treatment of Cancer;BioNanoScience;2024-08-30

2. Small molecule anticancer drugs approved during 2021–2022: Synthesis and clinical applications;European Journal of Medicinal Chemistry;2024-06

3. Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives;American Society of Clinical Oncology Educational Book;2024-06

4. Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis;Acta Pharmacologica Sinica;2024-05-17

5. CDK4/6 inhibitors in lung cancer: current practice and future directions;European Respiratory Review;2024-01-31